Summary
Becton Dickinson & Co. (BDX) reported strong financial performance for the fiscal year ending September 30, 2011. The company's revenues increased by 6% to $7.8 billion, driven by volume growth and favorable foreign currency translation, despite challenging economic conditions and a slight decrease in pricing. BD successfully integrated two key acquisitions: Accuri Cytometers, Inc. and Carmel Pharma Inc., strengthening its offerings in the life sciences and medical devices sectors, respectively. The company also continued its commitment to shareholder returns through significant share repurchases and dividend payments, while maintaining a strong balance sheet and cash flow from operations.
Financial Highlights
55 data pointsBeta
Financial Statements
Beta
| Revenue | $7.58B |
| Cost of Revenue | $3.63B |
| Gross Profit | $3.96B |
| R&D Expenses | $470.00M |
| SG&A Expenses | $1.82B |
| Operating Expenses | $5.92B |
| Operating Income | $1.67B |
| Interest Expense | $84.00M |
| Net Income | $1.27B |
| EPS (Basic) | $5.75 |
| EPS (Diluted) | $5.62 |
| Shares Outstanding (Basic) | 221.18M |
| Shares Outstanding (Diluted) | 226.28M |
Key Highlights
- 1BD reported a 6% increase in worldwide revenues to $7.8 billion for fiscal year 2011, driven by volume increases and favorable foreign exchange, despite pricing pressures.
- 2The company completed two strategic acquisitions: Accuri Cytometers, Inc. for $205 million and Carmel Pharma Inc. for $287 million, enhancing its capabilities in flow cytometry and closed-system drug transfer devices.
- 3BD's Medical segment experienced revenue growth of 5.6% to $4.0 billion, led by strong performance in Pharmaceutical Systems and international safety-engineered products.
- 4The Diagnostics segment saw a 7.0% revenue increase to $2.5 billion, driven by sales of safety-engineered products and growth in automated diagnostic platforms.
- 5The Biosciences segment's revenues grew by 6.7% to $1.3 billion, primarily due to instrument and reagent sales in the Cell Analysis unit.
- 6The company repurchased $1.5 billion of its common stock and paid $361 million in dividends, demonstrating a commitment to shareholder returns.
- 7BD maintained a strong financial position with $1.7 billion in cash flow from operating activities and $1.6 billion in cash and equivalents at year-end.